LLY•benzinga•
Eli Lilly's Oral GLP-1 Drug Orforglipron Hits Phase 3 Goals In Diabetes Trial, Stock Soars
Summary
Eli Lilly's oral GLP-1 drug orforglipron met key Phase 3 goals in type 2 diabetes, lowering A1C and weight with a favorable safety profile.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 17, 2025 by benzinga